New statewide plan aims to eliminate cervical cancer in Texas by 2032

fighting cancer

The five-year plan was launched during the CPRIT 2026 Innovations Conference in Galveston this month. Photo via Unsplash.com

MD Anderson, on behalf of a coalition of health systems, has announced a new plan to eliminate cervical cancer in Texas.

The five-year Texas Lone Star Cervical Cancer Elimination Plan was launched during the Cancer Prevention and Research Institute of Texas (CPRIT) 2026 Innovations Conference in Galveston this month.

The plan focuses on three major pillars with goals to be achieved by 2032:

HPV vaccination: Increase the percentage of Texas boys and girls up to date on human papillomavirus (HPV) vaccination by age 15 from 50.5 percent to 80 percent
Cervical cancer screening: Raise the share of Texas women up to date on cervical cancer screening from 64 percent to 80 percent
Timely follow-up, diagnosis and treatment: Ensure 80 percent of women receive diagnostic follow-up and treatment when needed through community outreach, patient navigation, provider training and survivorship support

Overall, the coalition wants to see fewer than four new cases of cervical cancer annually per 100,000 Texas women by 2032, according to a news release from MD Anderson. Currently, Texas has an incidence rate of 9.5 women per 100,000 diagnosed with cervical cancer, compared with 7.5 women per 100,000 nationally.

“Texas has the tools to prevent nearly every case of cervical cancer, but tools can save lives only when people can utilize them,” Dr. Ernest Hawk, vice president and division head of Cancer Prevention and Population Sciences at MD Anderson, said in the release. “The Lone Star Cervical Cancer Elimination Plan gives us a shared roadmap to vaccinate more of our children, screen more of our women and make sure every abnormal result leads to care. With innovations like HPV self-collection and the commitment of partners across the state, elimination is within reach.”

About 40 other hospitals, health care organizations and companies join MD Anderson in the coalition that launched the Lonestar Plan. Those based in Houston include Houston Methodist, Rice University, UTHealth Houston, Texas Children's Hospital, Houston Health Department and others.

The CPRIT also announced its Texans Conquer Cancer Awards and its CPRIT Champion awards during the Innovations Conference this week. Several are based in Houston, including:

Zhiqiang An, co-founder of CrossBridge Bio, Director of the Texas Therapeutics Institute, and Vice President of Drug Discovery at the University of Texas Health Science Center at Houston
Dr. Abbey Berenson, Director of the UTMB Center for Interdisciplinary Research in Women's Health Care
Dr. Michael Taylor, Chair of Pediatric Neuro-Oncology at Texas Children's Cancer and Hematology Center and Director of Texas Children's Pediatric Brain Tumor Research Program

To date, the CPRIT has awarded more than $4.2 billion in grants to fight cancer in the state. Over the summer, it awarded four $2 million grants to institutions in Houston and Bryan for the creation or expansion of “core” cancer research facilities.

Texas Medical Center Innovation recently announced that its $2 million grant would renew its Accelerator for Cancer Therapeutics for five years. Read more from TMCi about the renewal here.

From Your Site Articles

The report considered patents, NIH funding, lab space, venture capital investments and the number of jobs. Photo via Pexels

Houston named the No.1 emerging city for biopharma in inaugural report

Biopharma Leader

Houston is ranked No.1 on the first-ever Next 10 U.S. Biopharma Clusters report published by Genetic Engineering & Biotechnology News (GEN).

The report, which ranks the best emerging hubs for life science activities, considered patents, NIH funding, lab space, venture capital investments, and the number of jobs in regions in cities, states and “clusters” across the U.S. GEN touts Houston as the top city for the biopharma industry due to a surge in funding, job creation, medical innovations and startup success.

Here’s how Houston ranked in the report’s different categories;

No. 1 for NIH funding with 2,262 awards totaling more than $1.25 billion
No. 2 for emerging regions for jobs, with 28,000 jobs
No. 2 for lab space, with roughly 8 million square feet in the market
No. 6 for patents, with 2,760 patent families

According to BioHouston chairman Jeff Wade, Houston secured half a billion dollars in venture capital funding in 2025 and 2026 to date.

The report called out major biopharm news out of Houston in the last few months, including Bristol Myers Squibb selecting Houston for its $1 billion, 600,000-square-foot manufacturing site and Eli Lily selecting Houston for its $6.5 billion, 236-acre manufacturing site. Both facilities will be located within Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston.

Houston startups like CrossBridge Bio and Duracyte were also mentioned in the report. CrossBridge, which develops antibody-drug conjugates for cancer, was acquired by Eli Lily in April for $300 million. Duracyte, a “living pharmacy” company, was launched out of Rice University’s biotech venture studio RBL LLC this spring and is backed by up to a $45 million Advanced Research Projects Agency for Health (ARPA-H) award.

The startup is working to commercialize its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR) technology, a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time.

“There’s a lot of great talent, but the unique advantage that we have is we are able to benefit from a lot of unique clinical infrastructure and clinician insights,” Omid Veiseh, Duracyte co-founder and managing partner of RBL LLC, told GEN. “There are a lot of clinicians here who are eager to partner on investigator-initiated trials.”

The report also touted Houston’s Texas Medical Center, home to the University of Texas MD Anderson Cancer Center and Baylor College of Medicine, and international partnerships like the recently expanded TMC Korea BioBridge.

Other cities to make the list include:

No. 2 Minneapolis-St. Paul
No. 3 Denver-Boulder
No. 4 St. Louis
No. 5 Dallas-Fort Worth

States to make the list include:

No. 1 Ohio (including Cincinnati, Cleveland, and Columbus)
No. 2 Indiana (including Indianapolis)
No. 3 Florida (including Jacksonville and Miami-Fort Lauderdale)
No. 4 Georgia (including Atlanta and Augusta)
No. 5 Wisconsin (including Madison and Kenosha)

Regional state clusters to watch include:

Phoenix
Pittsburgh
Greater Richmond, Virginia
South Carolina
Utah

See the full report here.

CrossBridge Bio co-founder and CEO Michael Torres. Photo via LinkedIn

Eli Lilly scoops up Houston biotech startup in $300 million deal

big pharma deal

Pharmaceutical giant Eli Lilly has acquired Houston biotech startup CrossBridge Bio, which develops antibody-drug conjugates for cancer, in a deal worth up to $300 million. The deal was celebrated by TMC Venture Fund and the University of Texas Health Science Center at Houston last week.

CrossBridge, founded in 2023, is developing ADCs based on research by Kyoji Tsuchikama and Zhiqiang An, both of UT Health Houston. Tsuchikama is an associate professor of medicinal chemistry and a globally recognized ADC pioneer, and An is a professor of molecular science and vice president of drug discovery.

Antibody-drug conjugates (ADCs) are a potent combination of targeted therapy and chemotherapy that kills cancer cells while saving healthy tissue.

Clinical trials for CrossBridge’s primary ADC candidate, CBB-120, are expected to start this year, pending approval from the U.S. Food and Drug Administration (FDA).

“I’m proud of how well our team has executed and advanced our platform in such a short time since the company’s founding,” Michael Torres, co-founder and CEO of CrossBridge, said in a news release. “By becoming a part of Lilly, a leader in patient-focused therapeutic development, we are well-positioned to further accelerate the clinical potential of this approach.”

Under the Lilly deal, CrossBridge shareholders were expected to receive an upfront payment along with a follow-up payment based on the achievement of certain milestones.

In 2024, CrossBridge closed a $10 million seed round. Among the investors in CrossBridge are the Texas Medical Center Venture Fund, CE-Ventures, Alexandria Venture Investments, Portal Innovations, Linden Lake Labs, and the Cancer Prevention and Research Institute of Texas (CPRIT). It was formed in TMC Innovation’s Accelerator for Cancer Therapeutics program."Built within the TMC ecosystem, CrossBridge Bio grew with the support, funding, and resources that helped shape its trajectory. TMC led the company's early financing and watched it evolve from its earliest days to its acquisition by Eli Lilly," William McKeon, president and CEO of the Texas Medical Center, shared in a LinkedIn post. "[This is a] strong reminder that breakthrough science and the right early backing can change what’s possible."

Portal Innovation's 30,000-square-foot Helix Park lab space is open for business. Photo via Portal Innovations/X

Innovative life science hub opens doors of Houston location, welcomes inaugural startups

ready to grow

A new life science-focused venture capital engine has officially opened offices in Houston.

Portal Innovations moved into a space at Helix Park in October. The offices are led by executive director Monique Knighten.

Knighten has been in Houston for 16 years, since she was a postdoc at the University of Texas Institute for Molecular Medicine. “It's like a lot of us. We come for a specific reason, and then we just find reasons to stay,” she says.

And now, that reason is to push the emerging Houston ecosystem forward by helping early-stage startups to build themselves toward success. Portal does that partly by providing capital, but besides cash investments, emerging companies need a physical infrastructure where their work can happen. They also need great people to support their cause at every step of development. To that end, networking and convening with beneficial people is key for Portal.

With locations already in Chicago, Boston and Atlanta, why did Portal choose Houston?

“If you take a look at where lots of scientific publications are coming from, if you look at where a lot of technology that eventually becomes commercialized, a lot of it will come initially from labs that are right here in Houston,” says Knighten. “Houston also has a great quality of life. That's really important so that startups need to be able to have a place where they can have their teams.”

And who has joined Portal in its 30,000-square-foot Helix Park lab space? March Biosciences, a cancer-focused cell therapy startup; Crossbridge Bio, responsible for a cancer therapeutic that just closed a $10 million seed round; Artidis, which is personalizing cancer diagnosis thanks to a new nanomedical biomarker technology; Spanios, which has created human model systems to help researchers better identify therapeutic options for solid tumors; Stingray Therapeutics, a cancer immunotherapy company working on metastatic or advanced solid tumors; Remunity Therapeutics, an immuno-oncology startup developing immune-stimulating antibody-drug conjugates that reactivate anti-tumor immune response; and Phiogen, which is doing promising work in the world of non-antibiotic anti-infectives.

The Cancer Focus Fund, an oncology-focused investment fund in partnership with The University of Texas MD Anderson Cancer Center is also sharing space with the burgeoning biomedical companies.

Even Texas Medical Center CEO Bill McKeon is excited to greet Portal.

“In Portal, we have a partner with a proven track record of leveraging venture capital funding, expert partners and strong programming to support dynamic, entrepreneurial businesses at pivotal moments of their growth. We look forward to building on our collective expertise and shared vision to further support the breakthroughs of early-stage life science ventures,” he says on the company’s website.

By working with Portal, each of the companies will benefit not only from Knighten’s expertise i building teams gathered from her time at Sartorius Stedim Biotech and decade with Miltenyi Biotec, but also that of the other Portal teams. Working on a national scale also gives the brands opportunities for national exposure. Just one more way, Houston’s ecosystem is continuing to move the needle both for the healthcare companies in it and the patients who will one day benefit.

This week's roundup of Houston innovators includes Michael Torres of CrossBridge Bio, Aileen Allen of Mercury, and Ryan Reisner of SeekerPitch. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across therapeutics, venture capital, and HR software.

Michael Torres, CEO of CrossBridge Bio

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via crossbridgebio.com

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

CrossBri dge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and Crescent Enterprises' VC arm, CE-Ventures. The round also included participation from Portal Innovations, Alexandria Venture Investments, Linden Lake Labs, and several pre-seed investors.

“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” Michael Torres, CEO of CrossBridge Bio, says in a news release. Torres served as an entrepreneur in residence of ACT. Continue reading.

Aileen Allen, venture partner at Mercury

Aileen Allen joined Mercury as venture partner and is on the board of the Houston Angel Network. Photo courtesy of Mercury

When Aileen Allen was contemplating a big career move — swapping sides of the table from tech company to venture investor — she was motivated by driving gender and experience diversity amongst decision makers.

"I've worked for VC-backed companies for most of my career and had the opportunity as an executive to be in the boardroom during that time," she says on the Houston Innovators Podcast. "One of my takeaways was that very few of my board members looked like me. I had one or two women on any of my boards at a time in totality, and very few of my board members had been operators."

"I'd really like to change that, and I'd like there to be better representation and diversification in the boardroom," she adds. Continue reading.

Ryan Reisner, president and founder of SeekerPitch

Ryan Reisner is the\u00a0president and founder of SeekerPitch and The Reisner Group. Photo via LinkedIn

Confident job seekers have mostly been of the mindset that if they can just get in front of an employer, they can sell themselves into an offer for the open position. The obstacle then, is getting through the screening process to get an actual interview.

Until recently, the price of admission for starting or progressing in a desired career was a resume and cover letter stellar enough to catch the eye of the human resources and recruiting team. Outside of being buried in the immense pile of resumes recruiters do not have the bandwidth to get to, standing out in the sea of candidates can be daunting.

Resumes do not tell the full story as it is and it’s almost impossible for applicants to put their potential, soft skills and work personality into a document to be reviewed. So, what’s the solution?

It is a multi-layered problem, which requires a multi-layered solution, but one of the options gaining steam in the recruitment space is provided by SeekerPitch, a Houston-based HR technology platform utilizing generative AI to make hiring and interviewing more efficient.

“I've noticed that there's a ton of people that slip through the cracks,” says Ryan Reisner, president and founder of SeekerPitch and The Reisner Group. “And we spend all our time interviewing people to see if they have the soft skills. Resumes are hard skills. And now with AI, anybody can build the same exact resume. Everybody can say they have communication skills, leadership skills, and a lot of people say they have those." Continue reading.

CrossBridge Bio, formed during the TMC Innovation’s Accelerator for Cancer Therapeutics program, closed a $10 million seed round led by TMC Venture Fund and CE-Ventures. Photo via Getty Images

Houston biotech startup secures $10M seed round to propel cancer-fighting therapy from bench to bedside

fresh funding

A Houston biotech company based off research out of UTHealth Houston has raised seed funding to continue developing its cancer-fighting therapeutic.

The company is working on the next-generation of antibody-drug conjugates (ADC) therapeutics that process dual payloads as targeted treatments for a set of challenging cancers. The innovative treatment is based on research from UTHealth experts Dr. Kyoji Tsuchikama and Dr. Zhiqiang An.

“Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments," Torres continues.

He explains that the funding will toward advancing CrossBridge's first development candidate, CBB-120, into preclinical non-GLP toxicology studies in addition to derisking the company’s proprietary linker technology with dual-payload applications, per the release.

As a result of the raise, William McKeon, president and CEO of the Texas Medical Center, and Damir Illich, manager of life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.

“We are proud to back CrossBridge Bio in their mission to develop the next generation of cancer therapies,” McKeon says in the release. “Their dual-payload ADCs are designed to deliver targeted drug release within cancer cells with greater stability, precision, and control. These breakthrough advancements have the potential to change patients’ lives worldwide and we look forward to helping drive their development.”

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

UH lands $3M grant to expand opioid overdose training

Overdose Response

The University of Houston has received a $3 million federal grant to expand its potentially life-saving overdose response training program.

The grant will support the Houston Health Department’s FRONTLINES program that trains first responders in Harris and Fort Bend counties to recognize opioid overdoses and administer the drug naloxone, which can counter the effects of an opioid overdose. The four-year grant comes from the Substance Abuse and Mental Health Services Administration within the Department of Health and Human Services, and it builds on eight years of work at UH, according to a release from the university.

As part of the expansion, UH medical, social work and psychology students will now also be able to take part in FRONTLINES’ overdose-response training. Some of the students will also be selected to help train community members, ultimately passing along the life-saving skills throughout Houston.

FRONTLINES is a collaboration with the City of Houston, the Fertitta College of Medicine, Baylor College of Medicine and the Houston Recovery Center. It was co-founded by Dr. James Bray, chair of the Department of Behavioral and Social Sciences at the University of Houston’s Tilman J. Fertitta Family College of Medicine, in 2018.

“When someone experiencing an opioid overdose is reached in time, naloxone can save their life,” Bray said in a news release. “We’ve seen the impact this training can have in Houston, and now we have an opportunity to extend that reach across Harris and Fort Bend counties, putting lifesaving knowledge and tools into the hands of more first responders.”

In 2024, around 450 residents of Harris County died from opioid overdoses, according to a Texas Department of State Health Services report. The report found that fentanyl was involved in about three-quarters of the deaths.

In 2025, UH also received a $2.6 million gift from the estate of Dr. William A. Gibson to expand its opioid research and develop a vaccine to help block fentanyl's effectiveness in entering the brain. The vaccine research is part of the Michael C. Gibson Addiction Research Program led by UH professor of psychology Therese Kosten and founding member of the UH Drug Discovery Institute Colin Haile. Read more about the grant and the vaccine’s development here.

Texas public libraries drive billions in economic impact, report finds

Beyond the Stacks

A new statewide study examining the economic impacts of public libraries has revealed they have generated over $3.8 billion in value to local communities — a return of $4.74 for every $1 invested.

The report, "Beyond the Stacks: Measuring the Economic and Community Value of Texas Public Libraries" was conducted by third-party consultancy JBK Economics Group in partnership with the Texas Library Association. About 300 of the total 513 public libraries in Texas participated in a survey for the report.

A major finding from the survey revealed that public libraries create billions in economic value for the communities they serve at a fraction of what it costs to pay employee wages and benefits, operating expenditures, and capital expenditures. About 11,200 jobs were directly and indirectly supported by public libraries, the report found.

The report found its $4.74 to $1 ratio by adding up the total value of the services provided by these institutions (an estimated $2.48 billion), and comparing it to total expenditures ($808.6 million).

"Public libraries had about the same economic footprint as the Texas motion picture and sound recording industry ($2.9 billion in Gross Domestic Product in 2024) or the Texas paper manufacturing industry ($4.0 billion in Gross Domestic Product in 2024)," the report said.

Many Houstonians are already familiar with Houston Public Library's expansive catalog and programming, but there are many more services the library provides that might fly under the radar. A few examples include access to subscription-based research databases and news outlets, and the Library of Things, a collection of cookware and bake ware, musical instruments, craft kits, and other tools or activity materials that are available for cardholders to borrow. Individual branches also provide free Wi-Fi, computer access, and meeting spaces.

Houston-area residents also have access to services at several other local libraries depending on their address, such as the Harris County Public Library, Montgomery County Memorial Library System, or Fort Bend County Libraries, just to name a few.

These are additional services and partnerships that Texas public libraries commonly provide, per the survey results:

93 percent provide voter registration and/or serve as voting locations
84 percent provide partnerships with local social services agencies
82 percent provide job application assistance
68 percent facilitate applications for government benefits
38 percent provide on-site social services
30 percent provide telehealth rooms and/or resources

"Public libraries are practical, welcoming and rooted in the communities they serve — they are unmistakably Texan," said Texas Library Association executive director Shirley Robinson in a press release. "This study puts a dollar value on the opportunities libraries create every day. Whether someone visits a library to apply for a job, access the internet, learn a new skill or simply find a new favorite book, those services create real value for Texans and their communities."

------

This article first appeared on CultureMap.com.

Rice University launches new venture fund for university-affiliated startups

startup support

Rice University has launched its new One Giant Leap Ventures Fund I, which will invest in the university’s spinouts and alumni-founded startups.

The early-stage institutional venture fund will function with a hybrid structure that allows for participation from traditional equity investors and philanthropic investors. According to the university, the fund will invest up to $500,000 per Rice-affiliated company.

To be considered eligible for funds, companies must use intellectual property licensed by the university or be led or founded by alumni.

One Giant Leap will draw on support and mentorship from Rice’s pool of 60,000 alumni and aims to create educational opportunities within the investment phases, work with graduate and undergraduate venture students, explore the scaling and commercialization of their ideas, and help investigate all the facets of venture capital.

“Rice alumni bring an extraordinary depth of experience as entrepreneurs, investors and industry leaders, and One Giant Leap creates new ways to put that expertise to work for the next generation of Rice innovators,” Stephen Bayer, vice president for development and alumni relations, said in a news release. “It strengthens the connection between our alumni and the university while giving them meaningful opportunities to mentor, advise and support Rice-affiliated companies as they grow.”

The fund held its first close in August and made its first investment into Rice brain health spinout Motif Neurotech. Led by Rice faculty member Jacob Robinson, Motif is working to commercialize a minimally invasive neurostimulator that targets treatment-resistant depression. In May, the FDA approved the company to move forward with its first clinical trial.

“Research produces breakthrough technologies and our academic environment forms outstanding entrepreneurs,” said Adrian Trömel, the fund’s managing director, a Rice alumnus and a startup founder who also serves as Rice’s interim chief innovation officer.

One Giant Leap joins the already long list of Rice-led programs that foster innovation, including the Liu Idea Labs for Innovation and Entrepreneurship’s Innovation Fellows and Summer Venture Studio, the Rice Alliance’s Business Plan Competition, the Ion District, Woodside Rice Decarbonization Accelerator, Rice Nexus, the Biotech Launchpad and RBL Ventures and its upcoming 200,000 square-foot research lab the Arc.

“With One Giant Leap, I am excited that we are creating a unique structure that brings together traditional investment and philanthropic participation to invest in and help catalyze our startups, engage the deep expertise within the Rice ecosystem and transform those strengths into real-world impact,” Trömel added in the release.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME